Can you take Nitrol Appli-Kit with Tetrabenazine?

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Anemia.

Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia. Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency. However, elevations of methemoglobin may also occur with commonly used dosages. While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Aortic Stenosis.

Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses. Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris. Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension. Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope. Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.

Tetrabenazine has a major potential interaction with Arrhythmia.

Tetrabenazine can cause an increase in the corrected QT interval. QT prolongation can lead to the development of ventricular arrhythmias. The use of tetrabenazine should be avoided in patients with congenital long QT syndrome and in patients with a history of arrhythmias.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Brain Tumor.

Organic nitrates and nitrites can increase cerebrospinal fluid pressure. Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.

Tetrabenazine has a moderate potential interaction with Breast Cancer.

Tetrabenazine can elevate serum prolactin concentrations. This should be considered when therapy will be prescribed in patients with previously detected breast cancer. Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis. If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Cerebrovascular Insufficiency.

Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses. Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris. Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension. Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope. Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Constrictive Pericarditis.

Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses. Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris. Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension. Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope. Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Constrictive Pericarditis.

The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy. In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling. Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Dehydration.

Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses. Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris. Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension. Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope. Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.

Tetrabenazine has a major potential interaction with Depression.

The use of tetrabenazine is contraindicated in patients with untreated or uncontrolled depression. Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior.

Tetrabenazine has a moderate potential interaction with Dysphagia.

Tetrabenazine reduces dopaminergic transmission and can be associated with esophageal dysmotility and dysphagia. Caution should be exercised when used in patients with conditions that predispose to dysphagia. Special caution is advised in patients with Huntington's disease as dysphagia is a common symptom and it could lead to aspiration pneumonia.

The nitroglycerin in Nitrol Appli-Kit has a minor potential interaction with Glaucoma/Intraocular Hypertension.

Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma. However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma. Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure. Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Head Injury.

Organic nitrates and nitrites can increase cerebrospinal fluid pressure. Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Heart Attack.

The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings. If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia. In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur. Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction. Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction. The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Heart Failure.

The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings. If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia. In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur. Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction. Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction. The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Hemodialysis.

The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension. Therapy with these agents should be administered cautiously in patients requiring hemodialysis. The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis. Nitroglycerin and isosorbide dinitrate are moderately dialyzed.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Hemorrhagic Stroke.

Organic nitrates and nitrites can increase cerebrospinal fluid pressure. Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.

Tetrabenazine has a major potential interaction with Huntington's Disease.

Patients with Huntington disease are prone to depression. Tetrabenazine can increase the risk of depression and suicidal thoughts and should be used with caution in patients with Huntington's disease. The benefits and risks of treatment should be considered before starting therapy, and patients should be under close observation for emergence or worsening of depression symptoms. The family and caregivers should also be informed of this risk and should be instructed to report any changes in behavior or any concerns to the treating physician.

Tetrabenazine has a moderate potential interaction with Huntington's Disease.

Tetrabenazine reduces dopaminergic transmission and can be associated with esophageal dysmotility and dysphagia. Caution should be exercised when used in patients with conditions that predispose to dysphagia. Special caution is advised in patients with Huntington's disease as dysphagia is a common symptom and it could lead to aspiration pneumonia.

Tetrabenazine has a moderate potential interaction with Hyperprolactinemia.

Tetrabenazine can elevate serum prolactin concentrations. This should be considered when therapy will be prescribed in patients with previously detected breast cancer. Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis. If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.

The nitroglycerin in Nitrol Appli-Kit has a moderate potential interaction with Hypertrophic Cardiomyopathy.

Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Hypotension.

Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses. Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris. Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension. Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope. Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.

Tetrabenazine has a moderate potential interaction with Hypotension.

Tetrabenazine can induce postural dizziness and syncope and should be used with caution in patients who are vulnerable to hypotension.

Tetrabenazine has a major potential interaction with Liver Disease.

The use of tetrabenazine is contraindicated in patients with hepatic impairment. The safety and efficacy of exposure to the drug and other metabolites are unknown and it is not possible to adjust the dosage in hepatic impairment to ensure safe use.

Tetrabenazine has a moderate potential interaction with Osteoporosis.

Tetrabenazine can elevate serum prolactin concentrations. This should be considered when therapy will be prescribed in patients with previously detected breast cancer. Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis. If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Pericardial Tamponade.

The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy. In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling. Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Pseudotumor Cerebri.

Organic nitrates and nitrites can increase cerebrospinal fluid pressure. Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Restrictive Cardiomyopathy.

The use of intravenous nitroglycerin is contraindicated in patients with constrictive pericarditis, pericardial tamponade, or restrictive cardiomyopathy. In these patients, cardiac output is dependent upon venous return, which can be reduced by nitroglycerin due to venous pooling. Also, nitroglycerin-induced hypotension may lead to paradoxical bradycardia and increased angina pectoris.

The nitroglycerin in Nitrol Appli-Kit has a major potential interaction with Shock.

Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses. Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris. Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension. Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope. Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.

Tetrabenazine has a moderate potential interaction with Syncope.

Tetrabenazine can induce postural dizziness and syncope and should be used with caution in patients who are vulnerable to hypotension.